Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6-11 Years of Age with Severe Atopic Dermatitis.
Saved in:
| Title: | Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6-11 Years of Age with Severe Atopic Dermatitis. |
|---|---|
| Authors: | Cork MJ; Sheffield Dermatology Research, University of Sheffield, Sheffield, UK.; Sheffield Children's Hospital Clinical Research Facility, Sheffield, UK., Thaçi D; Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany., Eichenfield LF; Departments of Dermatology and Pediatrics, University of California, San Diego, CA, USA.; Division of Pediatric and Adolescent Dermatology, Rady Children's Hospital, San Diego, CA, USA., Arkwright PD; Lydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester, UK., Chen Z; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA., Thomas RB; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA., Kosloski MP; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA., Dubost-Brama A; Sanofi, Chilly-Mazarin, France., Prescilla R; Sanofi, Cambridge, MA, USA., Bansal A; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA., Levit NA; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA. noah.a.levit@gmail.com. |
| Source: | Dermatology and therapy [Dermatol Ther (Heidelb)] 2023 Nov; Vol. 13 (11), pp. 2697-2719. Date of Electronic Publication: 2023 Sep 26. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Healthcare Communications Country of Publication: Switzerland NLM ID: 101590450 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2193-8210 (Print) NLM ISO Abbreviation: Dermatol Ther (Heidelb) Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2193-8210 |
|---|---|
| DOI: | 10.1007/s13555-023-01016-9 |
